Table 1 Patient characteristics at the initiation of second JAK inhibitor

Age, years, median (IQR)

56.5 (48.3, 61.0)

Female, n (%)

30 (93.8)

Disease duration, years, median (IQR)

13.5 (8.4, 21.5)

RF positive, n (%)

26 (81.3)

Anti-CCP Ab positive, n (%)^a

23 (85.2)

Erosion on x-ray, n (%)

26 (81.3)

Number of bDMARDs prior to the first JAKi, median (IQR)

1.0 (0.0, 2.0)

First JAKi, n (%)

Tofacitinib

30 (93.8)

Baricitinib

2 (6.3)

Duration of first JAKi exposure, months, median (IQR)

8.0 (3.5, 17.0)

Reason for discontinuation of first JAKi, n (%)

Primary failure

16 (50.0)

Secondary failure

6 (18.8)

Adverse events

10 (31.3)

Number of bDMARDs between JAKis, median (IQR)

1.0 (1.0, 2.0)

Interval between JAKis, months, median (IQR)

10.0 (3.0, 22.0)

Second JAKi, n (%)

Tofacitinib

2 (6.3)

Baricitinib

29 (90.6)

Upadacitinib

1 (3.1)

Concomitant medication

Methotrexate, n (%)

22 (68.8)

Methotrexate dose, mg/week, median (IQR)

10.0 (9.4–13.1)

Glucocorticoid, mg/day^b, median (IQR)

5.0 (0.0, 5.0)